Brief Title
Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy
Official Title
Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy
Brief Summary
Subjects who previously took part in the FT500-101 study and received allogeneic NK cell immunotherapy will take part in this long term follow-up study. Subjects will automatically enroll into study FT-003 once they have withdrawn or complete the parent interventional study. The purpose of this study is to provide long-term safety and survival data for subjects who have participated in the parent study. No additional study drug will be given, but subjects can receive other therapies for their cancer while they are being followed for long term safety in this study.
Detailed Description
This is a multicenter, non-interventional, observation study designed to provide long-term safety and efficacy data on subjects who have participated in a prior Fate Therapeutics interventional study of FT500 cellular immunotherapy. Subjects will be contacted every six months (± one month), beginning six months after subject completion or withdrawal from the FT500-101 study.
Study Type
Observational
Primary Outcome
Overall Survival (OS) post-Infusion
Condition
Advanced Solid Tumor
Intervention
Allogeneic natural killer (NK) cell
Study Arms / Comparison Groups
Treatment with Fate Therapeutics' FT500 Cellular Immunotherapy
Description: Long Term follow-up of subjects who have received an allogeneic, iPSC-derived NK cell in a previous trial.
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Genetic
Estimated Enrollment
76
Start Date
June 11, 2019
Completion Date
December 2037
Primary Completion Date
February 2034
Eligibility Criteria
Inclusion Criteria: - Subjects who received an allogeneic, iPSC-derived NK cell in a Fate Therapeutics interventional study - Subjects who have provided Informed consent prior to their study participation Exclusion Criteria: - Not Applicable
Gender
All
Ages
18 Years - N/A
Accepts Healthy Volunteers
No
Contacts
Jeff Chou, MD, (858) 875-1800, [email protected]
Location Countries
United States
Location Countries
United States
Administrative Informations
NCT ID
NCT04106167
Organization ID
FT-003
Responsible Party
Sponsor
Study Sponsor
Fate Therapeutics
Study Sponsor
Jeff Chou, MD, Study Director, Fate Therapeutics
Verification Date
October 2021